Francisco Pontes

Francisco Pontes


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2017 in Journal of Venomous Animals and Toxins including Tropical Diseases
Verified
Journal Article
Open access
PDF file
RTRicardo Teixeira-Araújo
Ricardo Teixeira-Araújo
PCPatrícia Castanheira
Patrícia Castanheira
LBLeonora Brazil-Más
Leonora Brazil-Más
FPFrancisco Pontes
Francisco Pontes
MAMoema Leitão de Araújo
Moema Leitão de Araújo
CCCarlos Corrêa-Netto
Carlos Corrêa-Netto
Snakebite treatment requires administration of an appropriate antivenom that should contain antibodies capable of neutralizing the venom. To achieve this goal, antivenom production must start from a suitable immunization protocol and proper venom mixtures. In Brazil, antivenom against South American rattlesnake (Crotalus durissus terrificus) bites is produced by public institutions based on the guidelines defined by the regulatory agency of the Brazilian Ministry of Health, ANVISA. However, each institution uses its own mixture of rattlesnake venom antigens. Previous works have shown that crotamine, a toxin found in Crolatus durissus venom, shows marked individual and populational variation. In addition, serum produced from crotamine-negative venoms fails to recognize this molecule. In this work, we used an antivenomics approach to assess the cross-reactivity of crotalic antivenom manufactured by IVB towards crotamine-negative venom and a mixture of crotamine-negative/crotamine-positive venoms. We show that the venom mixture containing 20% crotamine and 57% crotoxin produced a strong immunogenic response in horses. Antivenom raised against this venom mixture reacted with most venom components including crotamine and crotoxin, in contrast to the antivenom raised against crotamine-negative venom. These results indicate that venomic databases and antivenomics analysis provide a useful approach for choosing the better venom mixture for antibody production and for the subsequent screening of antivenom cross-reactivity with relevant snake venom components.

18 August 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
LCLuis Eduardo Ribeiro da Cunha
Luis Eduardo Ribeiro da Cunha
ASAdilson A. Stolet
Adilson A. Stolet
MSMarcelo Abrahão Strauch
Marcelo Abrahão Strauch
VPVictor Augusto Augusto Roncaglia Roncaglia Pereira
Victor Augusto Augusto Roncaglia Roncaglia Pereira
CDCarlos H. Dumard
Carlos H. Dumard
JSJerson Silva
Jerson Silva
We used the trimeric spike (S) glycoprotein (residues 1-1208) in the prefusion conformation to immunize horses for production of hyperimmune globulins against SARS-CoV-2. Serum antibody titers measured by anti-spike ELISA were above 1:1,000,000, and neutralizing antibody titer was 1:14,604 (average PRNT 90 ), which is 140-fold higher than the average neutralizing titer of plasma from three convalescent COVID-19 patients analyzed for comparison. Using the same technology routinely used for industrial production of other horse hyperimmune products, plasma from immunized animals was pepsin digested to remove the Fc portion and purified, yielding a F(ab’) 2 preparation with PRNT 90 titers 150-fold higher than the neutralizing titers in human convalescent plasma. Repeating the hyperimmunization in a second group of horses confirmed the very high neutralizing titers in serum and in a GMP clinical F(ab’) 2 lot. Virus-neutralizing activity in samples from mice that received the F(ab’) 2 preparation was detected even three days after injection, indicating an appropriate half-life for therapeutic intervention. These results supported the design of a clinical trial (identifier NCT04573855 ) to evaluate safety and efficacy of this horse F(ab’) 2 preparation.

29 February 2016 in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
Verified
Journal Article
Open access
PDF file
FPFrancisco Pontes
Francisco Pontes
HZHelena Pereira da Silva Zamith
Helena Pereira da Silva Zamith
Avaliação da característica de personalização dos medicamentos magistrais manipulados pelas farmácias comunitárias com Autorização Especial quanto à individualização da dose